Pittsburgh Technology Council Names Category Leaders on October 12, 2017
PITTSBURGH, PA – Carmell Therapeutics, a privately-owned biotechnology company focused on the development and commercialization of innovative Plasma-based Bioactive Materials (PBMs), today announced that the Pittsburgh Technology Council has named it a Tech 50 Category Leader in the Innovator of the Year: Life Sciences Category.Read More >
Harvard John A. Paulson School of Engineering and Applied Sciences website.
A physician can make a positive impact on every patient, but an engineer who develops the right biomedical device could potentially help millions of people suffering from an illness or injury.
Alumna Stephanie Kladakis, S.B. ’96, is that engineer.Read More >
Carmell Therapeutics, a biotechnology company focused on developing and commercializing regenerative medicine technologies, announced today that on June 30, 2017 it closed a $4M Series B financing that will be used to advance its first product candidate, Bone Healing Accelerant, to phase III clinical development. Carmell received strong support from current investors, Pittsburgh Life Sciences Greenhouse, Harbor Light Capital, Newlin Investments and BlueTree Capital Group and welcomed new investor Keiretsu Forum Capital.Read More >